Skip to search formSkip to main contentSkip to account menu

KRN 5500

Known as: 6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-beta-L-mannohepto-pyranosyl]amino-9H-purine, KRN-5500, KRN5500 
A semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Therapy of B-cell chronic lymphocytic leukemia (CLL) is currently palliative, emphasizing the need for identification of new… 
2003
2003
Neuropathic pain is a significant clinical problem. Currently, there are no drugs that produce complete amelioration of this type… 
2002
2002
KRN5500 is a highly active new semi‐synthetic water‐insoluble anticancer agent. The only mechanism of anticancer activity of… 
2001
2001
Abstract. Purpose: KRN5500, a novel spicamycin derivative, shows the greatest activity against a human tumor xenograft model and… 
2000
2000
We studied the effects of a spicamycin derivative, KRN5500, on two animal models of neuropathic pain (Chung and Bennett models… 
Highly Cited
1999
Highly Cited
1999
For intravenous (i.v.) injection of a water‐insoluble antitumor drug, KRN5500, we have successfully incorporated KRN5500 into… 
1997
1997
The spicamycin analogue KRN5500 (NSC 650426; SPA) is derived from Streptomyces alanosinicus. The unique structure contains a… 
1995
1995
Spicamycin (SPM), produced by Streptomyces alanosinicus, induces potent differentiation in a human leukemia cell line, HL60. One… 
1994
1994
KRN5500, (6-[4-Deoxy-4-(2E,4E)-tetradecadienoylglycyl]amino-L-glycero - beta-L-mannoheptopyranosyl]amino-9H-purine), was semi…